Agribank to become land bank by March
The restructuring of Agribank to land bank is expected to be complete by end of March, according to Lands, Agriculture, Water and Rural Resettlement Minister Dr Anxious Masuka.
Glencore seals Zambia copper sale
Glencore has agreed to sell its stake in Mopani Copper Mines to the Zambian government for $1.5 billion, but will get just $1 upfront.
China vows no “policy cliff” in 2021 – Xinhua
BEIJING, Jan. 19 (Xinhua) — China will not see a “policy cliff” in 2021 as the country aims to keep its macro policies consistent, stable and sustainable to support steady economic recovery, an official said Tuesday.
Postal and courier services not spared by Covid 19
The postal and courier services sector has not been spared by Covid 19 as financial year 2020 third quarter figures still trail behind the pre-pandemic period.
Dividends for First Mutual Properties shareholders
First Mutual Properties shareholders are set to receive a cumulative $7 million dividend for the quarter to September 30, 2020.
Land Bank has posted a R172 million interim loss for 2020
The Land Bank has posted a R172 million interim loss for the six months ended 30 September.
ZSE tipped for another bullish year
Business Writer The Zimbabwe Stock Exchange is expected to continue on an upward trajectory in 2021 in spite of the headwinds currently bedevilling the economy, a leading local asset management…
Industry seeks extension of business hours
The Employers Confederation of Zimbabwe (EMCOZ), has approached Government seeking an extension of business hours from 8 am to 5 pm in order to save businesses.
Some key questions answered on COVID-19 vaccines for African countries
Vaccines for COVID-19 are generating a lot of talk. To shed some light on which vaccines are available for countries in sub-Saharan Africa, and how the process will work, The Conversation Africa’s Ina Skosana and Ozayr Patel asked Benjamin Kagina to answer a few questions.
Johnson & Johnson coronavirus vaccine generates immune response, few side effects, in early trials
(CNN)- Early stage trials of Johnson & Johnson’s experimental coronavirus vaccine show it generated an immune response in nearly all volunteers, with minimal side-effects, after a single dose.











